Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Q2 Earnings Top Estimates, View Up

by Zacks Equity Research

The growing adoption of the PASCAL Precision system in Europe and the United States and Edwards' premium products across all regions have driven Edwards Lifesciences' (EW) Q2 revenues.

Boston Scientific (BSX) Q2 Earnings Beat, Margins Improve

by Zacks Equity Research

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the second quarter.

CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View

by Zacks Equity Research

CONMED's (CNMD) adjusted second-quarter earnings and sales recover from the disruption in the last two quarters due to implementation of a new warehouse management system.

Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance

by Zacks Equity Research

Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

West Pharmaceutical (WST) Q2 Earnings Beat, HVP Drives Sales

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.

Chemed (CHE) Q2 Earnings Miss Estimates, '23 EPS View Down

by Zacks Equity Research

Chemed's (CHE) second-quarter 2023 performance reflects strength in the VITAS segment, while expenses weigh on margins.

Align Technology (ALGN) Q2 Earnings Beat, Gross Margin Up

by Zacks Equity Research

Align Technology (ALGN) delivers impressive earnings in the second quarter of 2023.

Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the second quarter.

Universal Health (UHS) Q2 Earnings Beat, Boosts '23 EPS View

by Zacks Equity Research

Universal Health's (UHS) Q2 results indicate improved patient admissions and solid segmental performance. Management currently expects adjusted EPS within $9.85-$10.50 for 2023.

Thermo Fisher (TMO) Q2 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Challenging macroeconomic conditions and slowdown in activities in China impede Thermo Fisher's (TMO) Q2 revenues.

Urmimala Biswas headshot

Medical Device Stocks' Q2 Earnings on Jul 27: BSX, LH & IART

by Urmimala Biswas

Medical Device companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, LH and IART fare this time.

Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up

by Zacks Equity Research

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the second quarter of 2023.

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

by Zacks Equity Research

Sector ETF report for IHI

NextGen (NXGN) Q1 Earnings Top Estimates, Revenues Surge Y/Y

by Zacks Equity Research

NextGen's (NXGN) first-quarter fiscal 2024 results reflect strength in its revenue sources.

Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Acadia Pharmaceuticals (ACAD) and Abbott (ABT) have performed compared to their sector so far this year.

Company News for Jul 21, 2023

by Zacks Equity Research

Companies In The News Are: KMI, UAL, ABT, IBM.

Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

by Zacks Equity Research

Abbott (ABT) delivers better-than-expected earnings and revenues in the second quarter of 2023

Abbott (ABT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Abbott (ABT) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 3.85% and 2.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

5 Big Cap Earnings Charts to Watch This Week

by Tracey Ryniec

We are going to get a good look at the global economy.

Shaun Pruitt headshot

2 Medical Stocks to Buy as Earnings Approach

by Shaun Pruitt

Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week's earnings lineup.

Here's Why You Should Add BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

Why Abbott (ABT) Might Surprise This Earnings Season

by Zacks Equity Research

Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.